RT Journal Article
SR Electronic
T1 Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP 81
DO 10.1186/s40425-016-0180-7
VO 4
IS 1
A1 Rini, Brian I.
A1 McDermott, David F.
A1 Hammers, Hans
A1 Bro, William
A1 Bukowski, Ronald M.
A1 Faba, Bernard
A1 Faba, Jo
A1 Figlin, Robert A.
A1 Hutson, Thomas
A1 Jonasch, Eric
A1 Joseph, Richard W.
A1 Leibovich, Bradley C.
A1 Olencki, Thomas
A1 Pantuck, Allan J.
A1 Quinn, David I.
A1 Seery, Virginia
A1 Voss, Martin H.
A1 Wood, Christopher G.
A1 Wood, Laura S.
A1 Atkins, Michael B.
YR 2016
UL http://jitc.bmj.com/content/4/1/81.abstract
AB Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complete responses, many of which have lasted for multiple decades. More recently, a large number of new agents have been approved for RCC, several of which attack tumor angiogenesis by inhibiting vascular endothelial growth factors (VEGF) and VEGF receptors (VEGFR), as well as tumor metabolism, inhibiting the mammalian target of rapamycin (mTOR). Additionally, a new class of immunotherapy agents, immune checkpoint inhibitors, is emerging and will play a significant role in the treatment of patients with RCC. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a Task Force, which met to consider the current role of approved immunotherapy agents in RCC, to provide guidance to practicing clinicians by developing consensus recommendations and to set the stage for future immunotherapeutic developments in RCC.Abbreviations:CNSCentral nervous systemCRComplete responseCWGCytokine working groupDFSDisease-free survivalECOGEastern Cooperative Oncology GroupFDAU.S. Food and Drug AdministrationHD IL-2High dose interleukin-2IFNInterferon-alphaIL-2Interleukin-2mRCCMetastatic RCCMSKCCMemorial-Sloan Kettering Cancer CentermTORMammalian target of rapamycinORROverall response rateOSOverall survivalPD-1Programmed death receptor 1PD-L1Programmed death ligand 1PRPartial responseRCCMetastatic renal cell cancerRFSRecurrence-free survivalSDStable diseaseSITCSociety for immunotherapy of cancerSQSubcutaneousTKITyrosine kinase inhibitorVEGFVascular endothelial growth factorVEGFRVascular endothelial growth factor receptor